Redemplo Injection, Solution
Product Images NDC 84141-025

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Redemplo (NDC 84141-025). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Arrowhead Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Plozasiran 01)

Chemical structure diagram of plozasiran, the active ingredient in REDEMPLO injection. The image includes the oligonucleotide sequence and detailed molecular structures labeled as R1 and R2 substituents, illustrating the chemical composition and bonding pattern of the compound.*

FDA Label Image

Figure 1 (Plozasiran 02)

A line graph showing median percent change from baseline in triglycerides over 12 months for placebo (pooled) and plozasiran 25 mg groups. The X-axis represents visits by month and the Y-axis shows percent change in triglycerides. Syringe icons indicate dosing schedule points. A table below shows the number of subjects at each visit for both groups.*

FDA Label Image

Figure 2 (Plozasiran 03)

A line graph showing median absolute values in triglycerides (mg/dL) over 12 months for two groups: Placebo (pooled) and Plozasiran 25 mg. The x-axis represents visits from baseline to month 12, and the y-axis shows triglyceride levels ranging to 3000 mg/dL. The graph includes a dosing schedule marked with syringe icons for Trial 1. Below the graph, the number of subjects at each visit is listed for both groups.*

FDA Label Image

Figure (Plozasiran 04)

An instructional diagram of a syringe before use, labeled with parts including plunger head, plunger rod, finger flange, plunger stopper, syringe barrel, and gray needle cap. The image visually identifies key components of a pre-use syringe assembly.*

FDA Label Image

Figure (Plozasiran 05)

An instructional diagram labeled "After Use" illustrating parts of a syringe-like injection device. It identifies the plunger head, plunger stopper, and needle components, likely for proper disposal or handling after administration.*

FDA Label Image

Figure A (Plozasiran 06)

An instructional illustration showing items included with the REDEMPLO injection, solution, 25 mg/.5 mL subcutaneous product from Arrowhead Pharmaceuticals, Inc. It depicts a prefilled syringe inside a carton, along with alcohol wipes, a cotton ball or gauze pad, an adhesive bandage, and a sharps disposal container.*

FDA Label Image

Figure B (Plozasiran 07)

An instructional illustration showing a hand grasping the barrel of a syringe inside an open box, with arrows indicating the motion to remove the syringe from the packaging.*

FDA Label Image

Figure C (Plozasiran 08)

An instructional diagram showing a labeled syringe with callouts indicating the location of the lot number and expiration date, highlighting where to find the expiration date on the syringe for the REDEMPLO injection solution.*

FDA Label Image

Figure D (Plozasiran 09)

An instructional illustration showing a clock face indicating 30 minutes with text advising to wait 30 minutes to reach room temperature before use.*

FDA Label Image

Figure E (Plozasiran 10)

An instructional illustration showing a prefilled syringe with a cap being removed or attached near the needle end. The image includes an eye symbol connected by dotted lines to the syringe, suggesting it is an instruction for visually inspecting the solution before use.*

FDA Label Image

Figure F (Plozasiran 11)

Illustration showing a subcutaneous injection device with a focus on the plunger or barrel section. The image includes stylized eye graphics and dotted lines pointing to parts of the injection device, emphasizing visual attention to its components.*

FDA Label Image

Figure G (Plozasiran 12)

An instructional diagram showing recommended injection sites for REDEMPLO (plozasiran) subcutaneous injection. Highlighted areas include the upper-outer arm for healthcare providers and caregivers, and the stomach and thigh for patient self-administration.*

FDA Label Image

Figure H (Plozasiran 13)

Illustration showing a pair of hands being washed with soap and water, with water running over them and soap lather visible. This instructional image likely demonstrates proper handwashing technique.*

FDA Label Image

Figure I (Plozasiran 14)

An illustration showing a hand applying a cloth or wipe to a surface or skin area, likely demonstrating a cleaning or preparation step prior to an injection.*

FDA Label Image

Figure J (Plozasiran 15)

An instructional illustration showing two hands preparing an injection. One hand holds a vial, pulling the cap off with an upward arrow indicating removal, while the other hand holds a syringe positioned below the vial, demonstrating the initial steps for subcutaneous injection preparation.*

FDA Label Image

Figure K (Plozasiran 16)

Illustration showing the proper technique for subcutaneous injection using a syringe. The image depicts a syringe held at a 45 to 90 degree angle to the skin, with an arrow indicating the direction to push the plunger for injection.*

FDA Label Image

Figure L (Plozasiran 17)

An instructional illustration showing how to administer a subcutaneous injection using a syringe. The image depicts a hand pressing the plunger head of the syringe all the way down into the skin of another person's arm, with accompanying text instructions to push the plunger head completely down.*

FDA Label Image

Figure M (Plozasiran 18)

An instructional illustration showing a hand holding a syringe above an arm, indicating upward motion with a blue arrow. The syringe appears to be for subcutaneous injection, relevant to the product REDEMPLO (plozasiran) injection.*

FDA Label Image

Figure N (Plozasiran 19)

An instructional illustration showing a hand disposing of a syringe and needle into a red biohazard sharps container. The syringe appears to be used for injection and is being carefully placed into the container's opening, emphasizing safe disposal of injection materials.*

FDA Label Image

Carton Label (25mg/0.5mL)

Carton packaging label for REDEMPLO 25 mg/0.5 mL (plozasiran) injection, solution for subcutaneous use. The label indicates the product is supplied by Arrowhead Pharmaceuticals, Inc., includes storage information, barcode, lot number, and expiration details. The design features the REDEMPLO logo and product usage instructions, showing it is a single-dose prefilled syringe.*

FDA Label Image

Container Label (25mg/0.5mL)

Label for REDEMPLO (plozasiran) injection 25 mg/0.5 mL, a single-dose solution for subcutaneous use. The label includes the NDC 84141-025-01, manufacturer Arrowhead Pharmaceuticals, Inc., and displays lot and expiration date placeholders. Also shows a barcode and prescription-only status.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.